688136 科兴制药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.735-11.081-4.8565.15711.014
总资产报酬率 ROA (%)0.388-6.143-3.0133.7137.846
投入资产回报率 ROIC (%)0.422-6.734-3.3414.1258.924

边际利润分析
销售毛利率 (%)71.38270.79175.36579.41079.983
营业利润率 (%)6.286-20.351-10.5307.62613.099
息税前利润/营业总收入 (%)8.039-18.179-9.4347.83214.763
净利润/营业总收入 (%)1.245-15.527-7.0547.50611.402

收益指标分析
经营活动净收益/利润总额(%)141.861104.758100.52938.389101.015
价值变动净收益/利润总额(%)-23.478-2.6022.28259.2400.000
营业外收支净额/利润总额(%)-13.7821.4760.363-2.483-0.436

偿债能力分析
流动比率 (X)1.5381.6922.6172.4203.730
速动比率 (X)1.3401.4062.2312.1353.473
资产负债率 (%)47.96146.19842.93832.46122.669
带息债务/全部投入资本 (%)42.49740.12135.78622.33314.827
股东权益/带息债务 (%)132.406146.148175.534338.666573.941
股东权益/负债合计 (%)108.073116.120133.080208.059341.125
利息保障倍数 (X)3.197-7.340-8.31820.0228.582

营运能力分析
应收账款周转天数 (天)81.85987.48092.14496.75696.863
存货周转天数 (天)143.704195.562211.192194.229185.425